Zuzanna Kozicka

Sep 26, 2024 | biorxiv.org | Woong Sub Byun |Zhe Zhuang |Jakub Chrustowicz |Zuzanna Kozicka

AbstractSmall molecules that induce protein interactions hold tremendous potential as new medicines, as probes for molecular pathways, and as tools for agriculture. Explosive growth of targeted protein degradation (TPD) drug development has spurred renewed interest in proximity-inducing molecules and especially Molecular Glue Degraders (MGDs).

Nov 16, 2023 | science.org | Huan Wang |Jeremy Owen |Jerrin Thomas George |Zuzanna Kozicka

Most biological processes are driven by proximity—our cells rely on the right proteins meeting at the correct time and place. With the help of small molecules, we can interfere with these encounters and block or force certain partnerships. A particularly promising strategy, targeted protein degradation, involves bringing together the degradation machinery, typically E3 ligase proteins, and a cellular “offender” (1).

Sep 7, 2023 | nature.com | Zuzanna Kozicka |Katherine A. Donovan |Marko Cigler |Jonathan L. Schmid-Burgk |Daniel Häussinger |Georg E. Winter | +4 more

AbstractMolecular glue degraders are an effective therapeutic modality, but their design principles are not well understood. Recently, several unexpectedly diverse compounds were reported to deplete cyclin K by linking CDK12–cyclin K to the DDB1–CUL4–RBX1 E3 ligase.